🔍 Observations
Topline
- Revenue from operations grew 12.8% YoY (₹9,360 Cr → ₹10,560 Cr), with Q4FY26 at ₹2,831 Cr — the strongest quarter of FY26, up 9.5% over Q4FY25’s ₹2,585 Cr.
- Sequential revenue momentum held: Q2→Q3→Q4 progression of ₹2,604 Cr → ₹2,604 Cr → ₹2,831 Cr signals an accelerating exit rate into FY27.
- Other income jumped 44% YoY (₹352 Cr → ₹507 Cr), driven by interest on FDs; operationally irrelevant but flatters total income.
Bottomline
- Net profit grew 17.2% YoY (₹2,191 Cr → ₹2,568 Cr), outpacing revenue — positive operating leverage at work.
- Q4FY26 PAT of ₹751 Cr was the highest quarterly print, up 13.4% over Q4FY25’s ₹662 Cr; sequential jump from ₹583 Cr reflects Q3’s one-time labour code charge of ₹74 Cr normalising out.
- Basic EPS expanded from ₹82.53 to ₹96.75 — a 17.2% YoY improvement on an unchanged share count.
Margins
- EBITDA (PBT ex-other income + depreciation + finance costs): FY26 = ₹3,462 – ₹507 + ₹463 + ₹23 = ₹3,441 Cr on revenue of ₹10,560 Cr → EBITDA margin 32.6% vs FY25: ₹2,916 – ₹352 + ₹402 + ₹2 = ₹2,968 Cr on ₹9,360 Cr → 31.7%. ~90 bps expansion YoY.
- Net profit margin (PAT/Revenue from ops): FY26 = 2,568/10,560 = 24.3% vs FY25 = 2,191/9,360 = 23.4%. ~90 bps improvement.
- Employee costs grew 16% YoY (₹1,243 Cr → ₹1,442 Cr) and material costs grew 14.6% (₹3,821 Cr → ₹4,378 Cr net of inventory change: ₹3,821–96 = ₹3,725 Cr FY25 vs ₹4,378–285 = ₹4,093 Cr FY26, +9.9%) — cost discipline preserved margin expansion.
Growth Trajectory
- Revenue CAGR trajectory: 12.8% in FY26; combined with margin expansion, the earnings growth of 17.2% YoY demonstrates operating leverage materialising at scale.
- CWIP nearly doubled (₹1,022 Cr → ₹2,113 Cr) and capex was ₹2,520 Cr in FY26 vs ₹1,438 Cr in FY25 — a 75% capex step-up signals management’s confidence in sustaining double-digit volume growth.
- Total equity grew from ₹14,969 Cr to ₹16,761 Cr, entirely through retained earnings; the asset base expanded from ₹16,932 Cr to ₹20,033 Cr — 18.3% in one year.
🧮 Profit & Loss Statement
🧮 Balance Sheet
🧮 Cash Flows Statement
🟢 Green Flags
- 17.2% PAT growth outpacing 12.8% revenue growth — operating leverage is real and compounding at Divi’s scale.
- EBITDA margin expanded ~90 bps to 32.6% — rare for a pharma API player facing input cost pressures; reflects pricing power and mix improvement.
- Debt-free balance sheet — near-zero borrowings (₹2 Cr wiped out by FY26); ₹3,414 Cr in liquid assets (cash + bank balances) with zero financial leverage risk.
- Operating cash flow surged 65.8% YoY (₹1,653 Cr → ₹2,738 Cr) — quality earnings, not accounting profits.
- ₹2,520 Cr capex in FY26 vs ₹1,438 Cr in FY25 — management deploying internal accruals aggressively into growth; no equity dilution, no debt.
- Highest-ever quarterly revenue and PAT in Q4FY26 — exit rate momentum strengthens FY27 base.
- EPS at ₹96.75 with consistent dividend payout (~₹797 Cr) — capital returns intact even during heavy capex cycle.
🔴 Red Flags
- Inventory surge of ₹718 Cr in FY26 (₹3,236 Cr → ₹3,954 Cr, +22%) — working capital build-up at a pace faster than revenue growth; warrants monitoring for demand realisation.
- CWIP of ₹2,113 Cr (up from ₹1,022 Cr) — large projects under execution carry commissioning risk; any delay converts to idle depreciation drag.
- Non-current liabilities tripled (₹511 Cr → ₹1,229 Cr) — primarily new labour code provisions (₹456 Cr other financial liabilities + ₹81 Cr provisions + ₹218 Cr other non-current liabilities) — these are cash outflows materialising in future periods.
- Other current assets nearly doubled (₹370 Cr → ₹721 Cr) — opaque line item; rapid growth without explanation is a balance sheet quality concern.
- Cash and cash equivalents fell sharply (₹415 Cr → ₹128 Cr) — offset by FD balances, but signals tighter near-term liquidity management as capex accelerates.
- Finance costs rose from ₹2 Cr to ₹23 Cr — modest in absolute terms but a directional shift from near-zero debt service costs for a historically debt-free company.
📊 Balance Sheet Analysis
- Equity-funded expansion: Total equity of ₹16,761 Cr vs total liabilities of ₹3,272 Cr; debt-to-equity effectively nil — fortress balance sheet.
- Liquid asset cover is strong: Bank balances + cash = ₹3,414 Cr; current ratio = ₹11,096 Cr / ₹2,043 Cr = 5.4x — ample short-term buffer even during aggressive capex.
- Fixed asset build accelerating: Gross block rose from ₹5,437 Cr to ₹6,515 Cr (+19.8%) with ₹2,113 Cr still in CWIP — asset base will expand materially once commissioned, setting up higher depreciation but also higher capacity.
- Trade receivables grew 9.3% (₹2,731 Cr → ₹2,984 Cr) against 12.8% revenue growth — receivables actually improved as a proportion of revenue; collection quality intact.
💰 Cash Flow Analysis
- Operating CF of ₹2,738 Cr vs PAT of ₹2,568 Cr — cash conversion ratio of 1.07x; earnings quality is high.
- Free cash flow (OCF – capex): ₹2,738 Cr – ₹2,520 Cr = ₹218 Cr — almost entirely consumed by capex; FY26 is a heavy investment year; FCF will remain constrained until CWIP is commissioned.
- Investing outflow of ₹2,219 Cr driven by ₹2,520 Cr capex net of ₹284 Cr interest income and FD churn — internal accruals are fully funding the capex cycle with no external borrowing.
- Financing outflow of ₹804 Cr is almost entirely dividends (₹797 Cr) — shareholder returns maintained even in peak capex; no equity issuance, no debt drawdown.
💡 Investment Outlook
Divi’s FY26 results confirm that the volume recovery cycle is translating into both topline growth and meaningful margin expansion — a combination that is rare in pharma APIs and historically the trigger for re-rating.
The near-doubling of capex and CWIP signals that management is building for the next growth leg, funded entirely through internal accruals on a debt-free balance sheet.
The primary near-term watch is whether the inventory build (₹718 Cr addition) reflects genuine demand pull or front-loaded procurement — resolution in H1FY27 will be a critical signal.
Strong OCF, expanding margins, and an accelerating exit rate make the structural case compelling; the capex cycle compressing FCF is a timing, not a structural, concern.
Disclaimer: This post features ChartAlert-AI-generated financial content which may contain inaccuracies or errors. This commentary is strictly for informational purposes and does not constitute a recommendation to buy or sell any security. Investors are responsible for performing their own due diligence; always consult with a licensed financial advisor before making investment decisions.
Beyond the Price Action: Fundamental Analysis is Coming to ChartAlert
ChartAlert is evolving into integrated research with a future update that will embed fundamental data into your workflow. Alongside technical analysis, the new release will allow access to financial data, quarterly results review, earnings call transcripts, and valuation tools, connecting price action with corporate performance for smarter, data‑driven decisions.